NorthWest Biotherapeutics Inc (NWBO)

[Umibe5690]

My post was specifically referring to what I think could happen if one or even both endpoints were missed wrt to share price upon top line announcement.

I laid out a scenario where even though both endpoints were missed, the share price might still rise due to impressive milestone/longtail data that addressed a relatively broad spectrum of glio IV cancers, e.g., M+ and MES that could account for about 60% of the ITT. In addition, missing the PFS endpoint may be overridden by the possibility that the RATE of progression slows dramatically after PFS eventing as the therapy takes hold as more time elapses.

Insofar as approval by RAs is concerned, I believe that it would issue even if both endpoints are missed due to results as stated above.

Hopefully, for the sake of share price appreciation, the endpoints are met in addition to the other, and I think, even more important metrics. The more obvious the data, the less you need to explain and be placed in a defensive position. To be sure, the naysayers are hoping for no less. JMHO.